Ad
related to: editas medicine stock news
Search results
Results from the WOW.Com Content Network
Editas Medicine (EDIT) closed at $76.14 in the latest trading session, marking a +0.29% move from the prior day.
Editas (EDIT) delivered earnings and revenue surprises of 6.90% and 99.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
About Editas Medicine As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and ...
Editas Medicine, Inc. ( NASDAQ:EDIT ) shareholders should be happy to see the share price up 27% in the last quarter... Investors one-year losses grow to 78% as the stock sheds US$94m this past ...
Here's the story behind the biotech stock that could be the best way to profit from the discovery of the century: CRISPR-Cas9 gene editing.
Editas (EDIT) reports narrower-than-expected loss in the third quarter of 2021 while its revenues marginally beat estimates. Focus remains on the development of lead candidate, EDIT-101.
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, [7] and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures; the name was changed to the current "Editas Medicine" two ...
In the latest trading session, Editas Medicine (EDIT) closed at $63.18, marking a +1.64% move from the previous day. Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know Skip ...
Ad
related to: editas medicine stock news